Prolor Biotech Receives Israeli Government Grant For Interferon Beta Development
IFN-Beta, which is indicated for the treatment of multiple sclerosis (MS), is currently marketed by Merck Serono as Rebif and by Biogen Idec as Avonex. Prolor Biotech has
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.